||Details concerning the Relocation of the Head Office
||Nippon Kayaku Announces Marketing Approval in Japan of Infliximab Biosimilar Monoclonal Antibody.
||Notice of Head Office Relocation
||Nippon Kayaku launches embolic microspheres, “HepaSphere® Microspheres” and “Embosphere® Microspheres” in Japan
||Inquiry form maintenance notification
||Submission of Application for Marketing Approval of CT-P13 Infliximab Biosimilar Monoclonal Antibody, in Japan
||Nippon Kayaku receives manufacturing (localization) and marketing authorization for embolic microspheres “HepaSphere® Microspheres” and “Embosphere® Microspheres” in Japan